Patents by Inventor David Calabrese
David Calabrese has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12434172Abstract: Systems and methods for managing fluid flow in and evaporating solvents from containers are provided. In various embodiments, systems of the present disclosure provide for cap or cover members operable to be provided with vials or containers comprising one or more fluids. The caps are further operable to direct air and gas flow into and out of the containers. In some embodiments, supporting structures and heating elements are provided to enhance and assist various processes.Type: GrantFiled: September 22, 2021Date of Patent: October 7, 2025Assignee: THE USA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICESInventors: Alexander Glenn Godfrey, Pranav Bende, Linus Eric Wallgren, David Calabrese
-
Patent number: 11898154Abstract: Disclosed are constructs and methods for expressing DNAs of interest in particular in non-primate eukaryotic host cells that display advantages with regard quantity and quality of expression including high stability of expression and, if appropriate, transport of the expression product out of the cell.Type: GrantFiled: February 1, 2014Date of Patent: February 13, 2024Assignee: SELEXIS S.A.Inventors: Valerie Le Fourn, Nicolas Mermod, Alexandre Regamey, Montse Buceta, Deborah Ley, Niamh Harraghy, Kaja Kostyrko, Pierre-Alain Giro, David Calabrese
-
Publication number: 20230193341Abstract: A transcriptomic analysis of genes consistently upregulated in high producer clones were each evaluated for their ability to increase the production of a protein of interest. The products of these genes (metabolism influencing products (MIP)), such as actin, Erp27, Erp57, Foxa1, PPAR, Ca3, and Tagap, could be sub-categorized into different functional categories such as signaling, protein folding, cytoskeleton organization and cell survival.Type: ApplicationFiled: October 23, 2019Publication date: June 22, 2023Applicant: Selexis SAInventors: Lucille Pourcel, Audrey Berger, Valerie Le Fourn, Severine Fagete, David Calabrese, Alexandre Regamey, Nicolas Mermod, Fabien Palazzoli, Pierre-Alain Girod
-
Publication number: 20230046668Abstract: Disclosed are cells that have stably integrated into their genomes exogenous nucleic acid sequences, such as transgenes, within or proximal to the integration site of a sequence comprising at least part of an endogenous retrovirus (ERV) or a LTR-retrotransposon (LTR-RT), or instead of a sequence encompassing an ERV or a LTR-RT that is part or was part of the genome of the cell, as well as method of producing and using such cells. Advantageously, a high level and/or stable production of the transgene expression product(s) can be achieved. Transgene integration and expression may be furthered by modulating the DNA repair pathways of the cell, e.g., by transiently expressing a gene encoding a protein that forms part of a DNA repair pathway during transgene integration.Type: ApplicationFiled: December 24, 2020Publication date: February 16, 2023Applicant: Selexis S.A.Inventors: Pierre-Olivier Duroy, Alexandre Regamey, Ghislaine Arib, Valerie Le Fourn, David Calabrese, Pierre-Alain Girod
-
Publication number: 20220177546Abstract: The present disclosure provides production systems and host cells to produce collagen 7 compositions comprising recombinant collagen 7 and/or functional variants thereof. The host cells are genetically engineered to stably express rCol7 and functional variants thereof. The collagen 7 composition can be used to restore collagen 7 levels in a subject in need, and for preventing, preventing the progression of, alleviating, and delaying the on-set of a skin condition, e.g., skin wound associated with dystrophic epidermolysis bullosa (DEB).Type: ApplicationFiled: March 27, 2020Publication date: June 9, 2022Inventors: Mark Desouza, Malini Viswanathan, Pierra-Alain Girod, Alexandre Regamey, Valerie Le Fourn, David Calabrese, John Gill, Megan Gottlieb, Amie Lundquist, Anna Tchoudakova, George Enriquez, Rahul Chelikani, Thomas Gagliardi, Tatiana Laivins, Hang Yuan
-
Publication number: 20210261516Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.Type: ApplicationFiled: May 3, 2021Publication date: August 26, 2021Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Servic, Yale UniversityInventors: John Schneekloth, JR., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, Peter Gareiss, David Calabrese, Elena Leon
-
Patent number: 11014902Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.Type: GrantFiled: March 30, 2020Date of Patent: May 25, 2021Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: John Schneekloth, Jr., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, David Calabrese, Elena Leon
-
Publication number: 20200308128Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.Type: ApplicationFiled: March 30, 2020Publication date: October 1, 2020Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServicInventors: John Schneekloth, JR., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, David Calabrese, Elena Leon
-
Patent number: 10669562Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.Type: GrantFiled: December 19, 2017Date of Patent: June 2, 2020Assignee: SELEXIS S.A.Inventors: Nicolas Mermod, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini
-
Publication number: 20200109421Abstract: Disclosed herein are methods of genome alteration, in particular genome editing in eukaryotic cells (e.g., mammalian cells), preferably, but not exclusively the integration of exogenous nucleic acids into the genome of a cell or a population of cells. Such methods include the modulation of cell cycle phases via external conditions such as physical separation, temperature, exposure to certain substances such as cell cycle modulators. Genome alteration is also effected via the use of enzymes such as nucleases and nickases and/or the modulation of DNA repair pathways.Type: ApplicationFiled: September 27, 2019Publication date: April 9, 2020Applicant: Selexis S.A.Inventors: Valerie Le Fourn, Severine Fagete, Alexandre Regamey, David Calabrese, Ghislaine Arib, Pierre-Alain Girod
-
Patent number: 10604499Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.Type: GrantFiled: December 12, 2018Date of Patent: March 31, 2020Assignee: The United States of America as represented by the Secretary, Department of Health and Human ServiceInventors: John Schneekloth, Jr., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, David Calabrese, Elena Leon
-
Publication number: 20190100503Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.Type: ApplicationFiled: December 12, 2018Publication date: April 4, 2019Applicants: The United States of America as represented by the Secretary, Department of Health and Human Service, Yale UniversityInventors: John Schneekloth, JR., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, Peter Gareiss, David Calabrese, Elena Leon
-
Patent number: 10196372Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.Type: GrantFiled: January 5, 2016Date of Patent: February 5, 2019Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Yale UniversityInventors: John Schneekloth, Jr., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, Peter Gareiss, David Calabrese, Elena Leon
-
Patent number: 10140776Abstract: Altering properties of rendered objects and/or mixed reality environments utilizing control points associated with the rendered objects and/or mixed reality environments is described. Techniques described can include detecting a gesture performed by or in association with a control object. Based at least in part on detecting the gesture, techniques described can identify a target control point that is associated with a rendered object and/or a mixed reality environment. As the control object moves within the mixed reality environment, the target control point can track the movement of the control object. Based at least in part on the movement of the control object, a property of the rendered object and/or the mixed reality environment can be altered. A rendering of the rendered object and/or the mixed reality environment can be modified to reflect any alterations to the property.Type: GrantFiled: June 13, 2016Date of Patent: November 27, 2018Assignee: MICROSOFT TECHNOLOGY LICENSING, LLCInventors: Julia Schwarz, Bharat Ahluwalia, David Calabrese, Robert C J Pengelly, Yasaman Sheri, James Tichenor
-
Publication number: 20180187229Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.Type: ApplicationFiled: December 19, 2017Publication date: July 5, 2018Applicant: SELEXIS S.A.Inventors: Nicolas Mermod, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini
-
Publication number: 20180030018Abstract: Methods for treating a tumor, such as a benign or malignant tumor, are disclosed herein. The methods include administering a therapeutically effective amount of a small molecule that selectively binds to and stabilizes G-quadruplex DNA in the promoter of the c-MYC gene to the subject. The methods are also of use to decrease the size and/or number of metastases. Compounds for use in the disclosed methods are also provided.Type: ApplicationFiled: January 5, 2016Publication date: February 1, 2018Applicants: The United States of America, as represented by the Secretary, Department of Health and Human Serv, Yale UniversityInventors: John Schneekloth, JR., John Simmons, Kenneth Felsenstein, Beverly Mock, Lindsey Saunders, Peter Gareiss, David Calabrese, Elena Leon
-
Patent number: 9879297Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.Type: GrantFiled: June 28, 2012Date of Patent: January 30, 2018Assignee: SELEXIS SAInventors: Mermod Nicolas, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini
-
Publication number: 20170358144Abstract: Altering properties of rendered objects and/or mixed reality environments utilizing control points associated with the rendered objects and/or mixed reality environments is described. Techniques described can include detecting a gesture performed by or in association with a control object. Based at least in part on detecting the gesture, techniques described can identify a target control point that is associated with a rendered object and/or a mixed reality environment. As the control object moves within the mixed reality environment, the target control point can track the movement of the control object. Based at least in part on the movement of the control object, a property of the rendered object and/or the mixed reality environment can be altered. A rendering of the rendered object and/or the mixed reality environment can be modified to reflect any alterations to the property.Type: ApplicationFiled: June 13, 2016Publication date: December 14, 2017Inventors: Julia Schwarz, Bharat Ahluwalia, David Calabrese, Robert CJ Pengelly, Yasaman Sheri, James Tichenor
-
Publication number: 20150361451Abstract: Disclosed are constructs and methods for expressing DNAs of interest in particular in non-primate eukaryotic host cells that display advantages with regard quantity and quality of expression including high stability of expression and, if appropriate, transport of the expression product out of the cell.Type: ApplicationFiled: February 1, 2014Publication date: December 17, 2015Inventors: Valerie Le Fourn, Nicolas Mermod, Alexandre Regamey, Montse Buceta, Deborah Ley, Niamh Harraghy, Kaja Kostyrko, Pierre-Alain Giro, David Calabrese
-
Publication number: 20130143264Abstract: The present invention relates to purified and isolated DNA sequences having protein production increasing activity and more specifically to the use of matrix attachment regions (MARs) for increasing protein production activity in a eukaryotic cell. Also disclosed is a method for the identification of said active regions, in particular MAR nucleotide sequences, and the use of these characterized active MAR sequences in a new multiple transfection method.Type: ApplicationFiled: June 28, 2012Publication date: June 6, 2013Applicant: SELEXIS SAInventors: Mermod Nicolas, Pierre Alain Girod, Philipp Bucher, Duc-Quang Nguyen, David Calabrese, Damien Saugy, Stefania Puttini